BIIB

$250.000.43%1.07

Biogen Inc (BIIB)

Date: O: H: L: C: Vol:

Schlusskurs vom Vortag:

$248.93

Offen:

$253.54

24-Stunden-Volumen:

293,274

Relatives Volumen:

0.21

Marktkapitalisierung:

$36.96B

Einnahmen:

$9.60B

Nettoeinkommen (Verlust:

$1.37B

KGV:

26.83

EPS:

$9.32

Netto-Cashflow:

$2.32B

1W Leistung:

+2.44%

1M Leistung:

+13.70%

6M Leistung:

+33.54%

1Y Leistung:

+67.41%

1-Tages-Spanne:

$246.49$255.35

1-Wochen-Bereich:

$246.25$258.73

52-Wochen-Spanne:

$148.51$258.78

Biogen Inc Aktie (BIIB) Unternehmensprofil

Firmenname

Biogen Inc

Sektor

Healthcare

Branche

Drug Manufacturers - General

Telefon

(781) 464-2000

Adresse

225 BINNEY STREET, CAMBRIDGE, MA, USA

Mitarbeiter

7,500

@biogen

Nächster Verdiensttermin

null

Neueste SEC-Einreichungen

SEC

BIIB-Diskussionen auf X

Marktkapitalisierung

Umsatz

Nettogewinn

Free Cashflow

ENV

Biogen Inc Aktie (BIIB) Hochstufungen & Herabstufungen

Datum	Aktion	Analytiker	Ratingänderung
2026-10-29	Hochstufung	Argus	Hold → Buy
2026-10-12	Hochstufung	JP Morgan	Neutral → Overweight
2026-08-13	Hochstufung	Wolfe Research	Peer Perform → Outperform
2026-07-13	Hochstufung	Truist	Hold → Buy
2026-06-08	Hochstufung	Needham	Hold → Buy
2026-05-15	Resumed	Evercore ISI	Outperform
2026-04-22	Hochstufung	UBS	Neutral → Buy
2026-04-20	Hochstufung	Wells Fargo	Equal Weight → Overweight
2026-04-14	Hochstufung	Piper Sandler	Neutral → Overweight
2026-02-20	Eingeleitet	Barclays	Equal Weight
2026-02-09	Bestätigt	H.C. Wainwright	Buy
2026-01-07	Resumed	UBS	Neutral
2025-12-10	Herabstufung	HSBC Securities	Hold → Reduce
2025-11-06	Hochstufung	Stifel	Hold → Buy
2025-09-25	Eingeleitet	Jefferies	Buy
2025-07-21	Resumed	Truist	Hold
2025-04-28	Herabstufung	HSBC Securities	Buy → Hold
2025-04-04	Herabstufung	Argus	Buy → Hold
2025-02-11	Eingeleitet	Bernstein	Mkt Perform
2025-01-02	Herabstufung	Piper Sandler	Overweight → Neutral
2024-12-20	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2024-12-16	Herabstufung	Stifel	Buy → Hold
2024-12-10	Resumed	BofA Securities	Neutral
2024-12-09	Herabstufung	Jefferies	Buy → Hold
2024-11-18	Herabstufung	Needham	Buy → Hold
2024-11-15	Eingeleitet	Wolfe Research	Peer Perform
2024-11-14	Eingeleitet	Citigroup	Neutral
2024-10-31	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2024-10-10	Resumed	Raymond James	Mkt Perform
2024-02-14	Bestätigt	Needham	Buy
2024-02-14	Herabstufung	Wells Fargo	Overweight → Equal Weight
2024-01-24	Herabstufung	UBS	Buy → Neutral
2023-12-20	Resumed	Cantor Fitzgerald	Overweight
2023-12-07	Hochstufung	Raymond James	Mkt Perform → Outperform
2023-09-06	Eingeleitet	HSBC Securities	Buy
2023-07-27	Eingeleitet	Scotiabank	Sector Outperform
2023-07-24	Bestätigt	UBS	Buy
2023-05-01	Hochstufung	Guggenheim	Neutral → Buy
2023-04-17	Hochstufung	Piper Sandler	Neutral → Overweight
2022-10-26	Hochstufung	Goldman	Neutral → Buy
2022-10-13	Hochstufung	Stifel	Hold → Buy
2022-10-07	Hochstufung	Argus	Hold → Buy
2022-09-28	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2022-09-28	Hochstufung	Mizuho	Neutral → Buy
2022-09-28	Hochstufung	Robert W. Baird	Neutral → Outperform
2022-04-18	Hochstufung	Wells Fargo	Equal Weight → Overweight
2022-03-08	Herabstufung	Stifel	Buy → Hold
2022-03-03	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2022-02-04	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2022-02-04	Bestätigt	Barclays	Equal Weight
2022-02-04	Bestätigt	BofA Securities	Neutral
2022-02-04	Bestätigt	Cowen	Outperform
2022-02-04	Bestätigt	Morgan Stanley	Overweight
2022-02-04	Bestätigt	Needham	Buy
2022-02-04	Bestätigt	Oppenheimer	Outperform
2022-02-04	Bestätigt	RBC Capital Mkts	Sector Perform
2022-02-04	Bestätigt	Robert W. Baird	Neutral
2022-02-04	Bestätigt	Wedbush	Neutral
2022-02-04	Bestätigt	Wells Fargo	Equal Weight
2022-02-04	Bestätigt	Wolfe Research	Peer Perform
2022-01-13	Herabstufung	Guggenheim	Buy → Neutral
2022-01-12	Herabstufung	Piper Sandler	Overweight → Neutral
2021-12-10	Resumed	Raymond James	Mkt Perform
2021-12-09	Resumed	Wells Fargo	Equal Weight
2021-12-06	Eingeleitet	Goldman	Neutral
2021-11-19	Eingeleitet	BMO Capital Markets	Outperform
2021-09-23	Eingeleitet	Needham	Buy
2021-06-18	Hochstufung	Piper Sandler	Neutral → Overweight
2021-06-14	Bestätigt	Truist	Buy
2021-06-11	Hochstufung	Bernstein	Mkt Perform → Outperform
2021-06-10	Hochstufung	UBS	Neutral → Buy
2021-06-08	Hochstufung	Atlantic Equities	Underweight → Neutral
2021-06-08	Bestätigt	Barclays	Equal Weight
2021-06-08	Hochstufung	Citigroup	Sell → Neutral
2021-06-08	Bestätigt	H.C. Wainwright	Buy
2021-06-08	Bestätigt	Jefferies	Buy
2021-06-08	Bestätigt	Morgan Stanley	Overweight
2021-06-08	Bestätigt	RBC Capital Mkts	Sector Perform
2021-06-08	Hochstufung	Robert W. Baird	Underperform → Neutral
2021-06-08	Bestätigt	Stifel	Buy
2021-06-08	Hochstufung	William Blair	Mkt Perform → Outperform
2021-06-07	Hochstufung	BofA Securities	Underperform → Neutral
2021-06-07	Hochstufung	Cowen	Market Perform → Outperform
2021-06-07	Hochstufung	Raymond James	Underperform → Mkt Perform
2021-02-05	Herabstufung	DZ Bank	Buy → Hold
2021-01-29	Hochstufung	Stifel	Hold → Buy
2020-11-10	Hochstufung	DZ Bank	Hold → Buy
2020-11-09	Herabstufung	Atlantic Equities	Neutral → Underweight
2020-11-09	Herabstufung	BofA Securities	Neutral → Underperform
2020-11-09	Herabstufung	Cowen	Outperform → Market Perform
2020-11-09	Bestätigt	H.C. Wainwright	Buy
2020-11-04	Hochstufung	BofA Securities	Underperform → Neutral
2020-11-04	Hochstufung	Jefferies	Hold → Buy
2020-11-04	Hochstufung	Wells Fargo	Equal Weight → Overweight
2020-10-28	Eingeleitet	UBS	Neutral
2020-07-27	Hochstufung	Morgan Stanley	Underweight → Overweight
2020-06-22	Herabstufung	Barclays	Overweight → Equal Weight
2020-06-22	Bestätigt	RBC Capital Mkts	Sector Perform
2020-06-09	Herabstufung	Bernstein	Outperform → Mkt Perform
2020-04-23	Herabstufung	Citigroup	Neutral → Sell
2020-04-23	Herabstufung	Raymond James	Mkt Perform → Underperform
2020-03-31	Eingeleitet	Wolfe Research	Peer Perform
2020-02-27	Eingeleitet	Barclays	Overweight
2020-01-27	Hochstufung	Canaccord Genuity	Hold → Buy
2019-12-13	Hochstufung	Credit Suisse	Underperform → Neutral
2019-12-02	Herabstufung	Robert W. Baird	Neutral → Underperform

Finanzdaten der Biogen Inc-Aktie (BIIB)

Zeitraum	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Enddatum des Zeitraums	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	9,890.60	9,675.90	9,835.60	10,173.40	10,981.70
Cost of revenue USD (M)	2,404.20	2,310.40	2,533.40	2,278.30	2,109.70
Gross profit USD (M)	-	-	7,302.20	7,895.10	8,872.00
Operating expenses USD (M)	8,334.10	7,769.90	6,005.40	4,303.30	6,031.30
Operating income USD (M)	-	-	1,296.80	3,591.80	2,840.70
Income before tax USD (M)	1,556.50	1,906.00	1,296.80	3,591.80	1,745.20
Income tax expense USD (M)	263.60	273.80	135.30	632.80	52.50
Net income USD (M)	1,292.90	1,632.20	1,161.50	2,961.60	1,727.60
Basic EPS USD/shares	8.83	11.21	8.02	20.96	10.44
Diluted EPS USD/shares	8.79	11.18	7.97	20.87	10.40
Basic weighted shares shares (M)	146.50	145.60	144.70	145.30	149.10
Diluted weighted shares shares (M)	147.10	145.90	145.60	146.00	149.60
Selling, general and administrative USD (M)	2,433.60	2,403.70	2,549.70	2,403.60	2,674.30

Biogen Inc-Aktie (BIIB) Insiderhandel

Grogan JaneOct 30 '26
Head of Research
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
695
Wert ($)
0
#Aktien Gesamt
4,753
Godbout SeanOct 02 '26
Chief Accounting Officer
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
27
Wert ($)
0
#Aktien Gesamt
1,467
Minor LloydAug 04 '26
Director
Transaktion
Proposed Sale
Kosten
$200.96
#Aktien
593
Wert ($)
119,169
#Aktien Gesamt
0
Minor LloydAug 04 '26
Director
Transaktion
Sale
Kosten
$200.96
#Aktien
593
Wert ($)
119,169
#Aktien Gesamt
2,689
Minor LloydAug 03 '26
Director
Transaktion
Proposed Sale
Kosten
$203.34
#Aktien
593
Wert ($)
120,581
#Aktien Gesamt
0
Minor LloydAug 03 '26
Director
Transaktion
Sale
Kosten
$203.34
#Aktien
593
Wert ($)
120,581
#Aktien Gesamt
3,282
Pangalos Menelas NJun 09 '26
Director
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
2,370
Wert ($)
0
#Aktien Gesamt
2,370
Keeney AdamMay 01 '26
Head of Corporate Development
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
939
Wert ($)
0
#Aktien Gesamt
6,820
Godbout SeanApr 01 '26
Chief Accounting Officer
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
181
Wert ($)
0
#Aktien Gesamt
1,396
Murphy NicoleFeb 12 '26
Head of Pharm Ops and Tech
Transaktion
Buy
Kosten
$195.03
#Aktien
3
Wert ($)
585
#Aktien Gesamt
19,611

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
Grogan Jane	Head of Research	Oct 30 '26	Option Exercise	$0.00	695	0	4,753
Godbout Sean	Chief Accounting Officer	Oct 02 '26	Option Exercise	$0.00	27	0	1,467
Minor Lloyd	Director	Aug 04 '26	Proposed Sale	$200.96	593	119,169	0
Minor Lloyd	Director	Aug 04 '26	Sale	$200.96	593	119,169	2,689
Minor Lloyd	Director	Aug 03 '26	Proposed Sale	$203.34	593	120,581	0
Minor Lloyd	Director	Aug 03 '26	Sale	$203.34	593	120,581	3,282
Pangalos Menelas N	Director	Jun 09 '26	Option Exercise	$0.00	2,370	0	2,370
Keeney Adam	Head of Corporate Development	May 01 '26	Option Exercise	$0.00	939	0	6,820
Godbout Sean	Chief Accounting Officer	Apr 01 '26	Option Exercise	$0.00	181	0	1,396
Murphy Nicole	Head of Pharm Ops and Tech	Feb 12 '26	Buy	$195.03	3	585	19,611

Biogen Inc Aktie (BIIB) Neueste Nachrichten

Nov 02, 2026

Form 4 Biogen Inc: Jane Grogan (Head of Research) For: 30 October By Investing.com - Investing.com South Africa

Nov 02, 2026

Form 4 Biogen Inc: Jane Grogan (Head of Research) For: 30 October By Investing.com - Investing.com India

Nov 02, 2026

Biogen's Jane Grogan Executes 695 RSU Conversion and Tax Withholding on October 30, 2026 - Kalkine Media

Nov 02, 2026

Research head acquires 695 Biogen (BIIB) shares through a stock award conversion. - Stock Titan

Nov 02, 2026

BTK Inhibitors Market to Expand During the Forecast Period (2026–2036) as Targeted Treatments Advance Across B-Cell Malignancies and Autoimmune Disorders | DelveInsight - GlobeNewswire Inc.

Nov 02, 2026

Oct 28, 2026

BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened - Zacks Investment Research

Oct 28, 2026

Big Day for Econ Data, Hyperscaler Earnings - Zacks Investment Research

Oct 28, 2026

How Are LLY's Neuroscience and Immunology Drugs Poised Ahead of Q3? - Zacks Investment Research

Oct 28, 2026

Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue Estimates - Zacks Investment Research

Oct 28, 2026

Oct 27, 2026

Boeing Stock Drops 7.5% After Q3 Earnings Miss Erases $10 Billion - 24/7 Wall St.

Oct 27, 2026

Biogen schedules October 28 results. Biogen stock trades 0.62 percent below its 52-week high - ad-hoc-news.de

Oct 27, 2026

Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? - The Motley Fool

Oct 27, 2026

Oct 26, 2026

Baron Health Care Fund: Q3 2026 New Positions And Exits - Seeking Alpha

Oct 26, 2026

Oct 23, 2026

Biogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains? - Zacks Investment Research

Oct 23, 2026

Oct 22, 2026

Chubb Breaks to a New 52-Week High at $363.95 - 24/7 Wall St.

Oct 22, 2026

Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight - GlobeNewswire Inc.

Oct 22, 2026

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Zacks Investment Research

Oct 22, 2026

Oct 21, 2026

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Zacks Investment Research

Oct 21, 2026

Oct 20, 2026

4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now - Zacks Investment Research

Oct 20, 2026

Oct 19, 2026

AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results - Zacks Investment Research

Oct 19, 2026

Oct 14, 2026

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? - Zacks Investment Research

Oct 14, 2026

Oct 13, 2026

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? - Zacks Investment Research

Oct 13, 2026

Brookfield Renewable Partners (BEP) Stock Price, News & Analysis - 24/7 Wall St.

Oct 07, 2026

Oct 06, 2026

Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research

Oct 06, 2026

Cisco Systems Surges 4.2% to $118.31 in a Single Session - 24/7 Wall St.

Oct 06, 2026

Oct 05, 2026

Biogen's Chief Accounting Officer Sean Godbout Reports October 2026 Stock Transactions via Form 4 - Kalkine Media

Oct 05, 2026

Oct 02, 2026

Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise? - Zacks Investment Research

Oct 02, 2026

Sep 26, 2026

Form 4 Boeing Co For: 26 September By Investing.com - Investing.com Nigeria

Sep 26, 2026

Form 4 Boeing Co For: 26 September - Investing.com India

Sep 26, 2026

Sep 24, 2026

Boeing Company (BA) Stock News & Articles - 247wallst.com

Sep 24, 2026

Sep 23, 2026

Biogen Inc. (BIIB) Stock Price, News, Quote & History - Yahoo! Finance Canada

Sep 23, 2026

Sep 20, 2026

Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook - The Motley Fool

Sep 20, 2026

Sep 16, 2026

Is Biogen Stock Outperforming the S&P 500? - Barchart.com

Sep 16, 2026

Sep 12, 2026

Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology - Yahoo Finance

Sep 12, 2026

Sep 11, 2026

Biogen (BIIB) Sees Canada Back LEQEMBI As Fair Value Stays In Focus - simplywall.st

Sep 11, 2026

Biogen (BIIB) Sees Canada Back LEQEMBI As Fair Value Stays In Focus - simplywall.st

Sep 11, 2026

Sep 10, 2026

Alzheimer’s Disease Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Alpha Cognition, Biogen, Eisai, Eli Lilly, Otsuka Pharma, Lundbeck, Suven Life Sciences, Roche - Barchart.com

Sep 10, 2026

Multiple Sclerosis Market Outlook 2036: Growth Trends, Competitive Landscape, and Future Opportunities by 2034 – DelveInsight | Biogen, Immune Response BioPharma, ImCyse, Atara Bio, Emerald Health - Barchart.com

Sep 10, 2026

Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch

Sep 10, 2026

BIIB Maintained by HSBC -- Price Target Raised to $175 - GuruFocus

Sep 10, 2026

Biogen Inc. stock gains on fresh analyst upgrades and strong Q2 figures - ad-hoc-news.de

Sep 10, 2026

Stifel reiterates Biogen stock rating on immunology pipeline - investing.com

Sep 10, 2026

Stifel reiterates Biogen stock rating on immunology pipeline By Investing.com - Investing.com Canada

Sep 10, 2026

Stifel reiterates Biogen stock rating on immunology pipeline - Investing.com

Sep 10, 2026

Ähnlich wie BIIB

Biogen Inc (BIIB)

Biogen Inc Aktie (BIIB) Unternehmensprofil

Marktkapitalisierung

Umsatz

Nettogewinn

Free Cashflow

ENV

Biogen Inc Aktie (BIIB) Hochstufungen & Herabstufungen

Finanzdaten der Biogen Inc-Aktie (BIIB)

Biogen Inc-Aktie (BIIB) Insiderhandel

Biogen Inc Aktie (BIIB) Neueste Nachrichten

Form 4 Biogen Inc: Jane Grogan (Head of Research) For: 30 October By Investing.com - Investing.com South Africa

Form 4 Biogen Inc: Jane Grogan (Head of Research) For: 30 October By Investing.com - Investing.com India

Biogen's Jane Grogan Executes 695 RSU Conversion and Tax Withholding on October 30, 2026 - Kalkine Media

Research head acquires 695 Biogen (BIIB) shares through a stock award conversion. - Stock Titan

BTK Inhibitors Market to Expand During the Forecast Period (2026–2036) as Targeted Treatments Advance Across B-Cell Malignancies and Autoimmune Disorders | DelveInsight - GlobeNewswire Inc.

BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened - Zacks Investment Research

Big Day for Econ Data, Hyperscaler Earnings - Zacks Investment Research

How Are LLY's Neuroscience and Immunology Drugs Poised Ahead of Q3? - Zacks Investment Research

Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue Estimates - Zacks Investment Research

Boeing Stock Drops 7.5% After Q3 Earnings Miss Erases $10 Billion - 24/7 Wall St.

Biogen schedules October 28 results. Biogen stock trades 0.62 percent below its 52-week high - ad-hoc-news.de

Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? - The Motley Fool

Baron Health Care Fund: Q3 2026 New Positions And Exits - Seeking Alpha

Biogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains? - Zacks Investment Research

Chubb Breaks to a New 52-Week High at $363.95 - 24/7 Wall St.

Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight - GlobeNewswire Inc.

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Zacks Investment Research

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Zacks Investment Research

4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now - Zacks Investment Research

AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results - Zacks Investment Research

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? - Zacks Investment Research

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? - Zacks Investment Research

Citigroup Drops 5% After Hours on Earnings Day - 24/7 Wall St.

Cisco Systems (CSCO) Stock Price, News & Analysis - 24/7 Wall St.

Lori Trahan Stock Trades and Disclosures - TechGraph

Daniel S Sullivan Stock Trades and Disclosures - TechGraph

Daniel S Sullivan Stock Trades and Disclosures - TechGraph

Form 4 Boeing Co For: 7 October By Investing.com - Investing.com UK

Brookfield Renewable Partners (BEP) Stock Price, News & Analysis - 24/7 Wall St.

Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research

Cisco Systems Surges 4.2% to $118.31 in a Single Session - 24/7 Wall St.

Biogen's Chief Accounting Officer Sean Godbout Reports October 2026 Stock Transactions via Form 4 - Kalkine Media

Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise? - Zacks Investment Research

Form 4 Boeing Co For: 26 September By Investing.com - Investing.com Nigeria

Form 4 Boeing Co For: 26 September - Investing.com India

Boeing Company (BA) Stock News & Articles - 247wallst.com

Biogen Inc. (BIIB) Stock Price, News, Quote & History - Yahoo! Finance Canada

Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook - The Motley Fool

Is Biogen Stock Outperforming the S&P 500? - Barchart.com

Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology - Yahoo Finance

Biogen (BIIB) Sees Canada Back LEQEMBI As Fair Value Stays In Focus - simplywall.st

Biogen (BIIB) Sees Canada Back LEQEMBI As Fair Value Stays In Focus - simplywall.st

Alzheimer’s Disease Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Alpha Cognition, Biogen, Eisai, Eli Lilly, Otsuka Pharma, Lundbeck, Suven Life Sciences, Roche - Barchart.com

Multiple Sclerosis Market Outlook 2036: Growth Trends, Competitive Landscape, and Future Opportunities by 2034 – DelveInsight | Biogen, Immune Response BioPharma, ImCyse, Atara Bio, Emerald Health - Barchart.com

Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch

BIIB Maintained by HSBC -- Price Target Raised to $175 - GuruFocus

Biogen Inc. stock gains on fresh analyst upgrades and strong Q2 figures - ad-hoc-news.de

Stifel reiterates Biogen stock rating on immunology pipeline - investing.com

Stifel reiterates Biogen stock rating on immunology pipeline By Investing.com - Investing.com Canada

Stifel reiterates Biogen stock rating on immunology pipeline - Investing.com

Ähnlich wie BIIB